Chemistry:Becampanel
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C10H11N4O7P |
| Molar mass | 330.193 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Becampanel (INN) (code name AMP397) is a quinoxalinedione derivative drug which acts as a competitive antagonist of the AMPA receptor (IC50 = 11 nM).[1][2][3][4] It was investigated as an anticonvulsant for the treatment of epilepsy by Novartis, and was also looked at as a potential treatment for neuropathic pain and cerebral ischemia, but never completed clinical trials.[1][2][3][5]
References
- ↑ 1.0 1.1 Comprehensive medicinal chemistry II. Elsevier. 2007. p. 290. ISBN 978-0-08-044513-7. https://books.google.com/books?id=fIMvAQAAIAAJ.
- ↑ 2.0 2.1 "Emerging drugs for epilepsy". Expert Opinion on Emerging Drugs 12 (3): 407–422. September 2007. doi:10.1517/14728214.12.3.407. PMID 17874969.
- ↑ 3.0 3.1 "Targeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy". Expert Opinion on Therapeutic Targets 18 (3): 319–334. March 2014. doi:10.1517/14728222.2014.874416. PMID 24387310.
- ↑ World Health Organization (1988). International Nonproprietary Names (INN) for Pharmaceutical Substances. W.H.O.. ISBN 9789240560369. https://books.google.com/books?id=dcF1nQEACAAJ.
- ↑ "Insights into the novel three 'D's of epilepsy treatment: drugs, delivery systems and devices". Drug Discovery Today 15 (17–18): 717–732. September 2010. doi:10.1016/j.drudis.2010.06.014. PMID 20603226.
 |  |
